Skin-of-Color Energy Device Safety Protocol for Aesthetic Practices

A 2026 narrative review published in Plastic and Reconstructive Surgery — authored by plastic surgeons from multiple institutions and covering noninvasive cosmetic treatments for Fitzpatrick IV–VI — states the core problem plainly: regardless of laser type, darker-skinned individuals are more likely to develop complications including prolonged erythema, wound infection, acne, milia, pigmentary changes, and scarring compared with lighter-skinned individuals. The review's general recommendations for laser use in darker skin are longer wavelength, minimal threshold fluence to avoid burns, shorter pulse width, lower energy, lower density, fewer passes, increased time between treatments, and appropriate post-treatment cooling.

These are the right principles. But principles are not a protocol. A practice needs a structured, documentable workflow that starts at intake, continues through parameter selection and treatment delivery, and extends to follow-up. This article provides that workflow — a skin-of-color safety protocol for aesthetic practices that use energy-based devices (lasers, RF microneedling, IPL, ultrasound).

This article is for med spa owners, medical directors, laser operators, and injectors who treat patients across the full Fitzpatrick spectrum and need a repeatable, auditable safety process — not just for individual treatments, but as a practice-wide standard.

Why a Separate Protocol Is Necessary

The Fitzpatrick skin phototype classification (I–VI) was developed to predict skin reactivity to ultraviolet radiation. It was not designed as a treatment-selection tool, and it has well-documented limitations: it does not account for ethnic variation within the same phototype, it underweights the risk of fibroproliferative scarring (keloids and hypertrophic scars) in skin of color, and it does not predict the threshold at which a specific laser wavelength will trigger melanocyte activation in an individual patient.

Despite these limitations, Fitzpatrick classification remains the standard entry point for device-parameter selection in aesthetic practice. The protocol described here uses Fitzpatrick as a starting framework and adds the clinical decision layers that Fitzpatrick alone cannot provide.

The clinical stakes

• Post-inflammatory hyperpigmentation (PIH) is the most common adverse effect of laser and energy-based device treatments. A systematic review and network meta-analysis published in Lasers in Surgery and Medicine (2026) found that PIH incidence peaks between 4 and 8 weeks post-treatment and that patients with higher Fitzpatrick skin types and those treated on non-facial areas are at elevated risk.
• Hypopigmentation is less common but more permanent — particularly after aggressive resurfacing in melanin-rich skin. Loss of melanocytes in the treated area can produce irreversible light patches.
• Keloid and hypertrophic scarring. Patients with Fitzpatrick IV–VI skin have a higher prevalence of fibroproliferative scarring. Any device that creates dermal injury (fractional lasers, RF microneedling, deep chemical peels) must account for this risk in both parameter selection and post-treatment wound care.
• Delayed thermal injury. Darker skin absorbs more energy across the visible and near-infrared spectrum. A fluence that is safe on Fitzpatrick II skin may cause excessive heat accumulation in Fitzpatrick V skin, even with the same wavelength.

Protocol Stage 1: Intake and Risk Assessment

Before any energy-based device treatment, the practice must complete a structured intake that goes beyond Fitzpatrick typing.

Fitzpatrick classification

Determine the patient's Fitzpatrick type using the standard questions (sunburn tendency, tanning behavior, not visual assessment alone). Document the type and the questions asked. Note that patients who are visually light-skinned but report easy tanning or hyperpigmentation after minor skin trauma may have a higher effective risk than their visual type suggests.

Extended risk-screening questionnaire

In addition to Fitzpatrick type, document:

• History of PIH. Has the patient developed dark spots after any previous skin injury — insect bites, acne, cuts, burns, previous laser treatments? A positive history is the single strongest predictor of future PIH and should trigger a more conservative treatment approach regardless of Fitzpatrick type.
• History of keloid or hypertrophic scarring. Personal or family history of raised scars after skin injury. If present, avoid aggressive dermal injury (deep fractional resurfacing, high-depth RF microneedling) in areas prone to keloid formation (chest, shoulders, jawline).
• Recent sun exposure. Active tan or recent sunburn increases epidermal melanin and therefore increases the risk of competitive absorption and PIH. Reschedule if the patient has significant recent sun exposure.
• Medications. Isotretinoin (6–12 month washout required before ablative procedures). Photosensitizing agents (tetracyclines, NSAIDs, St. John's wort). Topical retinoids (discontinue 1 week before treatment to prevent overpenetration and PIH). Hydroquinone (document if the patient is currently using it — it may affect pigmentation assessment).
• Recent procedures. Chemical peels, microneedling, or other energy-based treatments within the past 4–6 weeks. Stacking treatments without adequate recovery time increases inflammation and PIH risk.
• Skin conditions. Active melasma, post-inflammatory hyperpigmentation, eczema, psoriasis, or active infection in the treatment area. Each of these changes the risk profile and may require treatment modification or deferral.

Documenting the decision

The intake record should include a treatment-risk classification:

• Standard risk. Fitzpatrick I–III, no PIH history, no keloid history, no complicating factors. Standard device parameters with routine test spot.
• Elevated risk. Fitzpatrick IV with no PIH history, or Fitzpatrick I–III with PIH history. Conservative parameters, mandatory test spot with extended observation, pre-treatment preparation recommended.
• High risk. Fitzpatrick V–VI, or any patient with PIH history and Fitzpatrick IV+. Maximum conservative approach, extended pre-treatment preparation, longest observation windows, lowest effective fluence.

This classification drives every downstream decision — parameter selection, pre-treatment preparation, treatment spacing, and follow-up cadence.

Protocol Stage 2: Pre-Treatment Skin Preparation

For elevated- and high-risk patients, pre-treatment skin preparation is not optional. The 2026 Plastic and Reconstructive Surgery review recommends pretreatment with topical retinoic acid to speed re-epithelialization and decrease the severity and duration of hyperpigmentation. The same review, along with the standard operating protocol published in the Journal of Cosmetic Dermatology, supports a multi-agent pre-treatment regimen for high-PIH-risk patients.

The pre-treatment regimen (2–4 weeks before treatment)

For patients classified as elevated or high risk:

• Hydroquinone 4–8% (or alternative brightening agent if the patient is hydroquinone-intolerant), applied twice daily. This suppresses melanocyte activity and reduces the melanin load in the epidermis before the inflammatory stimulus of the laser treatment. For chemical-peel pretreatment in darker skin, the 2026 Plastic and Reconstructive Surgery review describes a formulation of 8% hydroquinone, 1% hydrocortisone, and 0.05% retinoic acid in an emollient cream base, applied twice daily for 4–6 weeks before the procedure. The patient should be advised that this is a reversible skin-lightening regimen intended to reduce PIH risk, not a permanent depigmentation treatment. The evidence for whitening agents on their own is mixed: the Lasers in Surgery and Medicine network meta-analysis found that whitening creams did not show a significant benefit over sunscreen across the pooled trials, and characterized their preventive efficacy as context-dependent and not broadly generalizable. The case for a priming regimen rests less on hydroquinone as a standalone intervention and more on reducing the epidermal melanin load before treatment and pairing that with the peri-procedural measures below — topical corticosteroids and aggressive cooling — that the same meta-analysis ranked among the most effective PIH-prevention strategies.
• Topical retinoic acid 0.025–0.05% (or retinol equivalent), applied nightly. Increases cell turnover, speeds re-epithelialization post-treatment, and enhances the penetration of hydroquinone. Discontinue 1 week before the procedure to prevent overpenetration and increased PIH risk during the treatment itself.
• Broad-spectrum sunscreen SPF 30+, applied daily. Strict photoprotection before and after treatment. Sun exposure during the pre-treatment period can increase epidermal melanin and undermine the priming regimen.
• Topical corticosteroid (for specific indications). Short-course topical corticosteroids before and after treatment may reduce inflammation and melanocyte activation. The Lasers in Surgery and Medicine meta-analysis found that short-term topical corticosteroids are simple, safe, and effective for reducing PIH, particularly for facial procedures.

Patient communication

The pre-treatment regimen requires patient compliance to be effective. Document that the patient was instructed on the regimen, the rationale, and the expected timeline. A patient who has not completed the pre-treatment preparation should not be treated at standard parameters — either delay the treatment or use more conservative settings.

Protocol Stage 3: Device and Parameter Selection

Wavelength selection by Fitzpatrick type

The general principle: longer wavelengths penetrate deeper and are absorbed less by epidermal melanin, making them safer for darker skin. This is well-established in the StatPearls laser skin-type recommendations (NCBI) and in clinical practice guidelines.

Parameter philosophy for skin of color

The specific numbers vary by device and indication, but the directional principles are consistent:

• Prefer photomechanical over photothermal mechanisms where possible. Picosecond lasers deliver energy in ultra-short pulses that create a photoacoustic (photomechanical) effect rather than a photothermal one. This is safer for skin of color because it minimizes heat diffusion into surrounding tissue — the mechanism that triggers melanocyte activation and PIH. A clinical study with picosecond lasers in skin of color demonstrated a PIH rate of only 4.65%, compared to 25–47% with Q-switched (nanosecond) lasers using photothermal energy. Where photomechanical devices are available and appropriate for the indication, they should be preferred for Fitzpatrick IV–VI patients.
• Lower fluence. Start at or below the minimum effective fluence for the indication. Increase only if the test spot shows no adverse reaction but insufficient clinical endpoint.
• Longer pulse duration. Allows heat to dissipate from the epidermis while still delivering energy to the target (follicle, vessel, pigment). The super-long-pulse concept is specifically designed for darker skin.
• Lower density (for fractional devices). Fewer microthermal zones per cm² means less total inflammatory stimulus and lower PIH risk.
• Fewer passes. One conservative pass is safer than two aggressive passes. The patient may need more sessions, but the per-session risk is lower.
• More treatment spacing. Standard treatment intervals (4–6 weeks) may be too aggressive for Fitzpatrick V–VI. Extending to 6–8 weeks allows complete resolution of inflammation before the next session.
• Aggressive cooling. Contact cooling, cryogen spray, or forced cold air — always active, never optional for skin of color. Cooling protects the epidermis from thermal injury.

The test spot is mandatory

For any patient classified as elevated or high risk, a test spot is not optional — it is a required step before the first full treatment session. The test spot protocol is covered in detail in a companion article on this site (see: laser hair removal patch-test protocol). Key points:

• Perform the test spot at the planned treatment parameters (or a conservative starting point).
• Observe for a minimum of 48 hours; for Fitzpatrick V–VI, observe for 7–14 days to capture delayed PIH.
• Document the test spot location, parameters, immediate response, and follow-up evaluation.
• Do not proceed with full treatment until the test spot is evaluated and cleared.

Protocol Stage 4: Treatment Delivery and Real-Time Monitoring

During the treatment session, the operator must monitor for signs of excessive tissue response in real time:

• Immediate epidermal whitening or graying. Stop. This indicates epidermal coagulation and imminent injury. Reduce fluence.
• Excessive erythema beyond the perifollicular or perivascular endpoint. May indicate epidermal thermal injury. Pause, apply cooling, and reduce parameters.
• Patient-reported burning or sharp pain beyond expected discomfort. Pain disproportionate to the procedure may indicate epidermal involvement. Stop and reassess.
• Visible edema beyond the treatment zone. May indicate excessive inflammatory response. Reduce fluence and density for subsequent passes.

The operator should communicate with the patient throughout the procedure, asking about comfort and sensation. In skin of color, the operator cannot rely on visual erythema alone — erythema may be difficult to appreciate on darker skin, and the first visible sign of injury may be epidermal change that has already occurred.

Document the actual parameters used, any adjustments made during the procedure, and the patient's reported comfort level.

Protocol Stage 5: Post-Treatment Care and Follow-Up Cadence

Immediate post-treatment

• Apply broad-spectrum sunscreen to the treated area before the patient leaves the office.
• Instruct the patient to avoid sun exposure for a minimum of 4 weeks.
• For elevated- and high-risk patients, initiate or continue the post-treatment topical regimen: hydroquinone (resume 4–10 days post-treatment once re-epithelialization is complete), topical corticosteroid for short-course inflammation reduction, and continued sunscreen.
• Provide written post-care instructions specific to the patient's skin type and the procedure performed.

Follow-up schedule

• 24–48 hours. For all patients. Assess for immediate adverse reactions (excessive erythema, edema, blistering). For Fitzpatrick I–III, this may be a phone or photo check. For elevated- and high-risk patients, an in-person or photo evaluation.
• 1 week. For elevated- and high-risk patients. Assess for early PIH, prolonged erythema, or unexpected healing. The PMC-published standard operating protocol for energy-based devices recommends review at 2–3 weeks for laser toning and 4–6 weeks for hair removal and ablative lasers, but high-risk patients benefit from an earlier check.
• 4 weeks. For all patients. Standard follow-up. Assess treatment response, skin healing, and any pigmentary changes. This is the minimum interval before considering a repeat treatment for most indications.
• 8 weeks. For elevated- and high-risk patients. PIH incidence peaks between 4 and 8 weeks. A follow-up at 8 weeks captures delayed PIH that was not visible at the 4-week check. If PIH is detected, initiate or continue the depigmenting regimen and extend the interval before the next treatment session.
• Before scheduling the next session. The patient's skin must be fully recovered — no active erythema, no PIH, no ongoing inflammation — before the next treatment. For high-risk patients, this may mean extending the interval beyond the standard 4–6 weeks.

What to do if PIH occurs

PIH after energy-based device treatment is not rare and is not necessarily a sign of negligence — but the practice's response must be prompt and documented:

1. Document the PIH. Photograph with consistent lighting and positioning. Note the onset timing relative to treatment.
2. Initiate treatment. Resume hydroquinone if not already in use. Add topical corticosteroid for active inflammation. Consider oral tranexamic acid for refractory cases (per the Lasers in Surgery and Medicine meta-analysis, intradermal TXA may be more suitable for non-facial areas where PIH risk is higher).
3. Delay the next session. Do not treat over active PIH. Wait until the hyperpigmentation has resolved or significantly improved.
4. Adjust future parameters. The patient has now demonstrated PIH susceptibility. Future treatments should use lower fluence, longer pulse duration, lower density, and longer treatment intervals.
5. Communicate with the patient. Explain that PIH is a recognized, treatable complication. Set realistic expectations for resolution time (weeks to months). Provide a clear treatment plan.

Building the Practice-Wide Protocol

A skin-of-color safety protocol should be a written document, approved by the medical director, integrated with the practice's laser safety program (if applicable — see ANSI Z136.3), and accessible to all clinical staff. It should cover:

1. Intake. The extended risk-screening questionnaire, treatment-risk classification, and documentation requirements.
2. Pre-treatment preparation. The priming regimen for elevated- and high-risk patients, with specific agents, concentrations, and durations.
3. Device and parameter selection. Wavelength, fluence, pulse duration, density, and cooling requirements by Fitzpatrick type and risk classification.
4. Test spots. When they are mandatory, how to perform them, and the observation window by risk level.
5. Treatment delivery. Real-time monitoring criteria and when to stop or adjust.
6. Post-treatment care. The topical regimen, activity restrictions, and written patient instructions.
7. Follow-up cadence. The follow-up schedule by risk level and what to assess at each visit.
8. PIH management. The response protocol if PIH is detected, including topical agents, treatment delay, parameter adjustment, and patient communication.

Sources

• PMC, "Noninvasive Cosmetic Treatments for Fitzpatrick IV–VI: A Narrative Review of Safety and Efficacy Guidelines" (Plastic and Reconstructive Surgery, 2026): https://pmc.ncbi.nlm.nih.gov/articles/PMC13012588
• PMC, "Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis" (Lasers in Surgery and Medicine, 2026): https://pmc.ncbi.nlm.nih.gov/articles/PMC12997392
• StatPearls (NCBI), "Laser Fitzpatrick Skin Type Recommendations": https://www.ncbi.nlm.nih.gov/books/NBK557626
• PMC, "Standard operating protocol for utilizing energy-based devices in dermatology" (Journal of Cosmetic Dermatology, 2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC11626368
• Dermatology Times, "Key Considerations and Best Practices for Aesthetic Procedures in Skin of Color": https://www.dermatologytimes.com/view/key-considerations-and-best-practices-for-aesthetic-procedures-in-skin-of-color
• Practical Dermatology, "Treatment Guidelines for the PicoWay Laser System in Skin of Color": https://practicaldermatology.com/topics/general-topics/treatment-guidelines-for-the-picoway-laser-system-in-skin-of-color/22087
• JCAD, "Postinflammatory Hyperpigmentation: A Review of the Epidemiology, Clinical Features, and Treatment Options in Skin of Color": https://jcadonline.com/postinflammatory-hyperpigmentation-a-review-of-the-epidemiology-clinical-features-and-treatment-options-in-skin-of-color
• FDA, "Aesthetic Cosmetic Devices": https://www.fda.gov/medical-devices/products-and-medical-procedures/aesthetic-cosmetic-devices